These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 24636379)

  • 1. The timing and probability of treatment switch under cost uncertainty: an application to patients with gastrointestinal stromal tumor.
    de Mello-Sampayo F
    Value Health; 2014 Mar; 17(2):215-22. PubMed ID: 24636379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV patients' decision of switching to second-line antiretroviral therapy in India.
    de Mello-Sampayo F
    AIDS Care; 2015; 27(7):900-6. PubMed ID: 25723906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
    J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the timing and probability of Presurgical Teledermatology: how it becomes the dominant strategy.
    de Mello-Sampayo F
    Health Care Manag Sci; 2022 Sep; 25(3):389-405. PubMed ID: 35040019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stochastic league tables: an application to diabetes interventions in the Netherlands.
    Hutubessy RC; Niessen LW; Dijkstra RF; Casparie TF; Rutten FF
    Health Econ; 2005 May; 14(5):445-55. PubMed ID: 15386648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia.
    Lu L; Peters J; Roome C; Stein K
    Int J Technol Assess Health Care; 2012 Jul; 28(3):241-8. PubMed ID: 22980700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of alternative treatments for depression in low-income women.
    Beil H; Beeber LS; Schwartz TA; Lewis G
    J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN; Baran RW; Kirbach SE; Dietz B
    Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The option value of delay in health technology assessment.
    Eckermann S; Willan AR
    Med Decis Making; 2008; 28(3):300-5. PubMed ID: 18480035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial.
    Henderson C; Knapp M; Fernández JL; Beecham J; Hirani SP; Cartwright M; Rixon L; Beynon M; Rogers A; Bower P; Doll H; Fitzpatrick R; Steventon A; Bardsley M; Hendy J; Newman SP;
    BMJ; 2013 Mar; 346():f1035. PubMed ID: 23520339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
    Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
    Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating option values into the economic evaluation of health care technologies.
    Palmer S; Smith PC
    J Health Econ; 2000 Sep; 19(5):755-66. PubMed ID: 11184803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?
    Uyl-de Groot CA; Giaccone G
    Curr Opin Oncol; 2005 Jul; 17(4):392-6. PubMed ID: 15933476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncertainty and the decision maker: assessing and managing the risk of undesirable outcomes.
    Gafni A; Walter S; Birch S
    Health Econ; 2013 Nov; 22(11):1287-94. PubMed ID: 23280702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inexact mixed risk-aversion two-stage stochastic programming model for water resources management under uncertainty.
    Li W; Wang B; Xie YL; Huang GH; Liu L
    Environ Sci Pollut Res Int; 2015 Feb; 22(4):2964-75. PubMed ID: 25226833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.
    Briggs AH; Weinstein MC; Fenwick EA; Karnon J; Sculpher MJ; Paltiel AD;
    Med Decis Making; 2012; 32(5):722-32. PubMed ID: 22990087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.